Cardiac device company AtriCure (NASDAQ:ATRC) has again been identified by an equities analyst as a likely acquisition target for a big medical device firm.Barrington Research listed Cincinnati-area AtriCure as among its top 15 stock picks for the year and called the company a strong candidate for a buyout, the Cincinnati Business Courier reported.“ATRC has the [...]

Medical device maker AtriCure (NASDAQ:ATRC) is looking to obtain regulatory clearance to use its AtriClip heart device on stroke patients.The Cincinnati-area company is planning next year to begin a clinical trial that will investigate the AtriClip for use in stand-alone procedures that involve exclusion of the left atrial appendage, a thumb-sized pouch on top of [...]

Cardiac device company AtriCure (NASDAQ:ATRC) has closed a feasibility clinical trial into a so-called “hybrid” procedure to treat atrial fibrillation, citing a change of plans in the study’s protocol.Cincinnati-area AtriCure’s DEEP AF feasibility study was investigating the hybrid procedure, which received that name because it combines catheter ablation, which occurs inside the heart, with a [...]

Cardiology devicemaker AtriCure (Nasdaq:ATRC) expects FDA approval of an atrial fibrillation label for a surgical ablation device in the first quarter of 2012.U.S. Food and Drug Administration approval of the atrial fibrillation (AF) label would make AtriCure the first company to have a device approved for the surgical treatment of AF and represent a significant [...]

Shares of cardiac device maker AtriCure (NASDAQ:ATRC) jumped 20 percent after an FDA panel recommended approving one of the company’s device for the surgical treatment of atrial fibrillation.AtriCure shares climbed the most in 16 months to around $12 in Thursday afternoon trading as enthusiastic investors reacted to positive news about the company’s Synergy ablation system [...]

Cardiac device maker AtriCure (NASDAQ:ATRC) saw its stock plunge Monday after an FDA report expressed “concerns” about a clinical trial for one of the company’s ablation devices.U.S. Food and Drug Administration staffers issued a (pdf) report in advance of an FDA advisory panel’s Wednesday meeting to review AtriCure’s application for approval of an atrial fibrillation [...]

Atrial fibrillation device company AtriCure (Nasdaq:ATRC) is among five medical companies most likely to be targeted for an acquisition in the next year, according to a new analyst report.In addition to Cincinnati-area AtriCure, the other device companies identified by Canaccord Genuity analyst Jason Mills as likely near-term acquisition targets were: HeartWare, Spectranetics, Thoratec and Volcano, [...]

A U.S. Food and Drug Administration panel will review cardiac device maker AtriCure‘s (NASDAQ:ATRC) application for a label for the surgical treatment of atrial fibrillation.On Oct. 26, the FDA’s Circulatory System Devices Panel will review the Cincinnati-area device maker’s Premarket Approval Application (PMA) for its Synergy ablation system, according to a statement from West Chester, [...]

Medical device giants looking to boost their atrial fibrillation product portfolios would do well to take a long, hard look at cardiac device-maker AtriCure (NASDAQ:ATRC).Things have been looking up recently for Cincinnati-area AtriCure, and if the company hits a few near-term milestones its got in its sights, its price to a strategic acquirer will only [...]

Cardiology medical device maker AtriCure (NASDAQ:ATRC) expects to receive U.S. regulatory clearance for a new cryoablation system by the end of next quarter.The company’s cryoICE BOX system would use extreme cold to freeze cardiac tissue in order to correct abnormal electrical signals that cause heart arrhythmia.The system was launched during the second quarter in Europe [...]